- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01666366
Comparison Between 2 Bilateral Internal Thoracic Artery Coronary Artery Bypass Grafting Configurations
Comparison of Bilateral Internal Thoracic Artery Revascularization Using in Situ or Y Graft Configurations: a Prospective Randomized Clinical, Functional and Angiographic Evaluation
Bilateral internal thoracic arteries (BITA) demonstrated superiority over other grafts to the left coronary system in terms of patency and survival benefit. Several BITA configurations are proposed for left-sided myocardial revascularization, but the ideal BITA assemblage is still unidentified.
From 03/2003 to 08/2006, 1297 consecutive patients underwent isolated bypass surgery in our institution. 481 patients met the inclusion criteria for randomization and 304 (64%) were randomized. Patients were allocated to BITA in situ grafting (n=147) or Y configuration (n=152) then evaluated for clinical, functional, and angiographic outcome after 6 months, 3 and 7 years . Patient telephone interviews were conducted every 3 months and a stress test performed twice yearly under the referring cardiologist's supervision. Angiographic follow-up was performed 6 months after surgery. The primary and secondary end points were, respectively, major adverse cerebro-cardiovascular events (MACCE) and the proportion of ITA grafts that were completely occluded at follow-up angiography.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design All patients referred for isolated surgical coronary revascularization from April 2003 to July 2006 were screened according to the inclusion criteria (Table 1). Patients were randomly assigned to undergo one of two alternative surgical strategies: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus) or BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration as described by Barra JA et al 3). Randomization was performed the day before the operation after the patient's record was reviewed without knowledge of the preoperative angiogram. Complementary grafting was performed with either a saphenous vein graft or a pedicled right gastroepiloic artery depending on the location and quality of the targeted coronary vessel, but also depending on the surgeon's choice. All patients were scheduled for a systematic angiography at 6 and 36 months following surgery. All patients gave written informed consent at the time of bypass surgery and before the angiographic investigation. The study protocol was approved by the Ethics Committee at our institution.
Patients From 2003 to 2006, 1297 consecutive patients underwent isolated bypass surgery at our institution. Of these, 481 patients (37%) met the inclusion criteria for enrolment in the study (Figure 1). Three hundred four of 481 patients (63%) were actually randomized. The remaining 177 patients were not randomized because of a) refusal of systematic angiographic control (85%) and b) logistic incapacity to randomize patients (15%). BITA grafting was performed with a in situ configuration in 147 patients and with a Y configuration in 152. Five patients initially allocated to the BITA in situ group were excluded for protocol violations. In these cases, the surgeon decided to deviate from the assigned revascularisation strategy in favor of a BITA Y configuration. Patient's demographics and clinical characteristics are shown in Table 2. The BITA were harvested and grafted as previously described 4-5. Operative characteristics are detailed in Table 3.
Postoperative management and follow-up Patients received prophylactic low dose fractionated heparin postoperatively, and 160 mg of aspirin daily starting on postoperative day 2. Patients were interviewed by telephone at 3 and 6 months and then twice yearly thereafter. If the patient had been hospitalized between interviews, in-patient records were obtained. Patients had a systematic stress test on a cycloergometer twice a year performed under the supervision of their referring cardiologist.
Follow-up angiography was scheduled at both 6 months and 3 years after surgery. Nitroglycerin (2 mg) was injected into each graft before filming. At least two orthogonal views of each ITA graft were obtained, with continued exposure as required to visualize distal runoff and the size of the target coronary bed.
Data analysis The clinical end point was occurrence of MACCE defined as a combined end-point including: death from any cause; perioperative myocardial infarction (occurring between 0 and 30 days); late myocardial infarction (occurring between 31 days and 6 years); additional cardiac surgery; coronary angioplasty; and stroke. Myocardial infarction was defined as the apparition of a new Q wave, a rise of more than 10 ng / ml of troponin in the early post operative period or any episode of chest pain with typical rise and fall of cardiac enzymes thereafter.
The angiographic end point was the proportion of ITA grafts that were completely occluded at follow-up angiography. Complete occlusion was defined as the absence of visible opacification of the target coronary vessel (TIMI flow grade 0).
All postoperative angiograms were independently reviewed by 2 investigators; discrepancies in patency definition were reviewed by a third investigator and resolved by consensus.
Statistical analysis We calculated that the enrolment of at least 152 patients per group would provide the study with 80% power to detect a relative reduction of 8 % in the rate of graft occlusion, from an estimated 10% with BITA Y grafting 6 to 2% with BITA in situ 7 grafting, assuming a 20% within-patient correlation for graft occlusion, a two-tailed test, and an alpha value of 0.05. Data are expressed as the mean ± 1 SD. In bivariate analyses, the association of independent variables with each outcome variable was tested with Chi square test for independent samples (binary variables).
All p-values are two-tailed. The Statistical Analysis Software (SAS, 9.1 releases, SAS Institute Inc., SAS Campus Drive, Cary, NC USA) was used in the statistical analysis.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques Universitaire St Luc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Angiographic evidence of severe (>70% by visual estimate) 3 vessels coronary obstruction
- Elective procedure
- Isolated CABG
- Age <75 years and life expectancy >5 years
Exclusion Criteria:
- Diabetes with a HbA1c >7.5
- FEV1 < 60 % predicted value
- Body mass index >35
- Reoperation
- Other configuration then LIMA -> LAD territory. RIMA -> LCX territory.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: In Situ Bilateral mammary grafting
Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
|
|
|
Active Comparator: Y composite Bilateral mammary grafting
Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
major adverse cerebro-cardiovascular events (MACCE)
Time Frame: 3 years
|
Data analysis The clinical end point was occurrence of MACCE defined as a combined end-point including: death from any cause; perioperative myocardial infarction (occurring between 0 and 30 days); late myocardial infarction (occurring between 31 days and 6 years); additional cardiac surgery; coronary angioplasty; and stroke.
Myocardial infarction was defined as the apparition of a new Q wave, a rise of more than 10 ng / ml of troponin in the early post operative period or any episode of chest pain with typical rise and fall of cardiac enzymes thereafter.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
graft patency
Time Frame: 3 years
|
The angiographic end point was the proportion of ITA grafts that were completely occluded at follow-up angiography. Complete occlusion was defined as the absence of visible opacification of the target coronary vessel (TIMI flow grade 0). All postoperative angiograms were independently reviewed by 2 investigators; discrepancies in patency definition were reviewed by a third investigator and resolved by consensus. |
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: David Glineur, MD PhD, Cliniques Universitaire St Luc
Publications and helpful links
General Publications
- Glineur D, Hanet C, Poncelet A, D'hoore W, Funken JC, Rubay J, Kefer J, Astarci P, Lacroix V, Verhelst R, Etienne PY, Noirhomme P, El Khoury G. Comparison of bilateral internal thoracic artery revascularization using in situ or Y graft configurations: a prospective randomized clinical, functional, and angiographic midterm evaluation. Circulation. 2008 Sep 30;118(14 Suppl):S216-21. doi: 10.1161/CIRCULATIONAHA.107.751933.
- Glineur D, Boodhwani M, Hanet C, de Kerchove L, Navarra E, Astarci P, Noirhomme P, El Khoury G. Bilateral Internal Thoracic Artery Configuration for Coronary Artery Bypass Surgery: A Prospective Randomized Trial. Circ Cardiovasc Interv. 2016 Jul;9(7):e003518. doi: 10.1161/CIRCINTERVENTIONS.115.003518.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BITA Y vs In Situ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
OPCI Core Laboratories LLCNot yet recruitingCoronary Artery Disease (CAD) | Coronary Calcification | Coronary Calcified Disease | Coronary Calcified NodulesUnited States
-
Shunmei MedicalNot yet recruitingCalcified Coronary Artery Disease | Coronary Arterial DiseasePoland, France, Spain
-
Kaohsiung Veterans General Hospital.CompletedChronic Coronary Syndrome; Coronary Artery Disease; Percutaneous Coronary InterventionTaiwan
-
University of GalwayNot yet recruitingMyocardial Ischemia | Percutaneous Coronary Intervention | Chronic Coronary Syndrome | Coronary Computed Tomography Angiography | Acute Coronary Syndromes (ACS) | Coronary Arteries Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Percutaneous Coronary Intervention | Coronary Stenosis | Coronary Restenosis | Coronary Artery Disease Progression | Coronary Stent Occlusion | Myocardial Revascularization
-
SUK MIN SEODaewoong Pharmaceutical Co. LTD.RecruitingCoronary Artery Disease (CAD) | Acute Coronary Syndromes (ACS)South Korea
-
Olivier F. BertrandRecruitingBifurcation Coronary Disease | Restenosis, Coronary | Coronary Arterial Disease (CAD)Canada
-
Ceric SàrlEuropean Cardiovascular Research Center; Philips Medical SystemsNot yet recruitingStable Coronary Artery Disease | Acute Coronary Syndromes
-
Cardiocentro TicinoNot yet recruitingMultivessel Coronary Artery Disease | Coronary Vessel | Acute Coronary Syndromes (ACS) | Vulnerable Coronary Plaques | Coronary Arterial Disease (CAD)Switzerland
Clinical Trials on Coronary artery bypass grafting
-
University of OuluKarolinska Institutet; Universita di Verona; University of Campania "Luigi Vanvitelli... and other collaboratorsRecruitingMyocardial Infarction | Coronary Artery Disease | Angina PectorisFinland
-
University of WuerzburgDeutsche Stiftung für HerzforschungUnknownStroke | Coronary Heart Disease | Cerebral InfarctionGermany
-
Austin HealthActive, not recruitingCoronary Artery Disease | AtherosclerosisAustralia
-
Armed Forces Institute of Cardiology, PakistanCompleted
-
Region Örebro CountySwedish Heart Lung Foundation; Regional Clinical ResearchCompleted
-
Federal State Budgetary Institution "Federal Center...CompletedCoronary Artery Disease | Ischemic Heart Disease | Coronary Artery Bypass GraftingRussian Federation
-
Medical University of SilesiaCompletedCoronary Artery Disease | Obesity | Angina Pectoris | Coronary; Ischemic
-
University Medical Center GroningenUnknownCoronary Artery Bypass | Cognitive DysfunctionNetherlands
-
Far Eastern Memorial HospitalCompletedCoronary Artery Disease
-
German Off Pump Coronary Artery Bypass in Elderly...Institut für Klinisch-Kardiovaskuläre Forschung GmbH; Deutsche Gesellschaft...Completed